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ABSTRACT 
Background: Management of hepatocellular carcinoma (HCC) is framed within standardized 
protocols released by Scientific Societies, whose applicability and efficacy in field practice 
need refining.  
Aim: We evaluated the applicability and effectiveness of guidelines for the treatment of HCC 
of the American Association for the Study of the Liver (AASLD). 
Methods: 370 consecutive cirrhotic patients with de-novo HCC in different stages (253 BCLC 
A, 66 BCLC B, 51 BCLC C) received treatment through a multidisciplinary team (MDT) 
decision and were followed until death or end of follow-up. 
Results: Adherent treatment to AASLD recommendations was in 205 (81%) BCLC A patients, 
36 (54%) BCLC B, and 27 (53%) BCLC C. Radiological complete response was achieved in 165 
(45%) patients after the first-line treatment, in 22 (19%) after a second-line and in 9 (23%) 
after a third line treatment. Adherence to AASLD recommendation allowed a lower yearly 
mean mortality rate in BCLC A patients compared to other treatment (5.0% vs 10.4% p = 
0.004), whereas upward treatment stage migration compared to the standard of care was 
associated to reduced yearly mortality in BCLC B (8.6% vs 20.7%, p = 0.029) and BCLC C 
(42.6% vs 59.0%, p = 0.04) patients.  
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Conclusions: HCC multimodality treatment including other than first-line therapy is common 
in clinical practice and impact on the achievement of complete response. Personalized 
treatment was able to provide survival benefits to patients whose profile is not accounted 
for by international recommendations, which need to be amended. 
 
Keywords: hepatocellular carcinoma, BCLC stage, HCC treatment, cirrhosis 
 
Key points 
 Multimodality treatment of HCC in the field practice in a tertiary referral center was 
reported.  
 Discrepancies from 2011 AASLD recommendations in HCC patients management were 
detailed. Outcome of second-, third- and forth-line HCC treatments, never considered in the 
AASLD recommendation, was reported.   
 Evidence of an increased survival for HCC treatment according to upward stage migration as 
compared to AASLD recommended treatment was reported in BCLC B and C patients. 
 Independent prognostic factors for BCLC A, B and C class were reported.  
 
INTRODUCTION 
Survival of patients with a hepatocellular carcinoma (HCC) largely depends on patient access 
to potentially curative therapies as dictated by disease stage classification based on tumor 
burden, liver impairment and performance status1-3. The multidimensional BCLC staging 
system which has been endorsed by the American (AASLD) and European (EASL) 
Associations for the Study of Liver Diseases and the European Organization for Research and 
Treatment of Cancer (EORTC), serves the purpose4-7. Liver transplantation (LT), surgical 
resection and local ablation have emerged as most effective options which provide 
significant survival benefits to patients with an early tumor (BCLC 0/A). Unfortunately, this is 
not the case for  the many patients harboring a greater tumor burden confined to the liver 
(intermediate stage BCLC B), who are not indicated to radical treatments but may still gain 
survival benefits by local treatments with transarterial chemoembolization (TACE). Finally, 
survival can still be improved in patients with advanced stage (BCLC C) tumor, following oral 
treatment with the multikynase inhibitor sorafenib.4-7 In real life, however, adherence to the 
therapeutic algorithms for HCC recommended by international societies may be 
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compromised by scarcity of liver donors for LT, strategic localization of an early tumor and 
presence of co-morbidities which unbalance the risk benefit ratio of non transplant curative 
treatments.7-9 Not surprisingly, therefore, TACE has gained popularity as a back-up 
treatment modality for an appreciable number of BCLC A patients who are unfit to radical 
therapies,. On the other hand relaxed criteria of selection have been applied to some BCLC 
B or C patients who ultimately underwent radical treatments in the case of tumor easily 
accessible, responsive to downstaging or accompanied by limited neoplastic thrombosis 
confined to peripheral branches of portal vein close to the tumor nodule. While the 
adherence to international guidelines for HCC treatment is far from being worldwide 
applied,7,10-16 there is scanty data on the outcome of HCC patients treated under the 
guidance of a multidisciplinary team (MDT), irrespective whether the patient adheres or not 
to AASLD guidelines. As a matter of fact, there is evidence of survival benefits provided by 
therapy of HCC outside the guidelines according to the migration stage concept, while data 
is limited on the impact of sequencing treatment following the first-line therapy.   
We therefore aimed to retrospectively evaluate the outcome of HCC treatment with respect 
to AASLD guidelines in consecutive patients attending a tertiary referral center, characterize 
predictors of outcome in patients treated out of guidelines and evaluate the impact of 
sequencing treatment after first-line therapy. 
 
MATERIAL AND METHODS 
Between January 2007 and December 2011, 280 consecutive cirrhotic patients with a de 
novo HCC diagnosed at the Center for Liver Disease, Fondazione IRCCS Cà Granda Ospedale 
Maggiore Policlinico, Milan, and 90 referred from General Practitioner or other Centres for 
the characterization of liver nodules, were enrolled in this observational longitudinal study 
and followed until death or last follow-up available up to December 2016. Patients with a 
previous diagnosis of liver cancer and those with poor liver function (Child–Pugh C), were 
excluded.   
After providing an informed consent, patients were enrolled following the collection of 
medical history, physical examination, complete blood count and biochemical tests. Etiology 
was classified as: HBV for serum HBsAg positivity, HCV for anti-HCV positivity, alcohol for 
alcohol intake higher than 60g/day in male and 40g/day in female for more than 10 years, 
mixed when more than one etiologic factor was recorded, other for autoimmune, 
metabolic, genetic etiology. All HBV patients were on antiviral therapy with nucleos(t)ide 
analogs. All HCV patients had serum HCV-RNA detectable. Clinical data were managed 
according to current Italian legislation for privacy, all personal data being blinded in the 
database. Cirrhosis was diagnosed either by histology or unequivocal clinical signs. HCC was 
diagnosed according to AASLD criteria.4,5 A US-guided fine-needle biopsy (FNB) was 
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performed to characterize nodules escaping radiological diagnosis, using a 21-gauge needle 
(Biomol, HS Hospital Service S.P.A., Aprilia, Italy). 
At enrollment, all patients underwent staging with a chest-CT scan and bone scintigraphy, 
and were stratified for HCC stage according to BCLC classification.1-3,17 Treatment modality 
was guided by a MDT composed by a transplant surgeon, a hepatologist and an 
interventional radiologist. Intention-to-treat decision was made according to the AASLD 
recommendations for HCC4,5. Radio frequency ablation (RFTA) was the first choice for tumor 
ablation, whereas alcohol injection (PEI) was a possible alternative in nodules up to 2 cm. 
Patients listed to LT were bridged with RFTA or TACE, in any case considering LT as the first-
line treatment in the analysis. Response to therapy was defined by modified RECIST 
criteria18 performing a CT or MRI one month apart local ablation and each cycle of TACE, 
two months apart resection, LT and first administration of sorafenib. Patients achieving a 
radiological complete response repeated a CT or MRI every three months for 24 months and 
subsequently were switched to US surveillance at 6 month intervals.  
In patients unfitting treatment criteria suggested by AASLD recommendations upward or 
downward stage migration was proposed. An upward stage migration were decided in the 
case of easy access to the upward treatment (i.e., HCC satellites <1cm close to the main 
nodules, more than one nodule in the same liver segment suitable for resection, easy video-
laparoscopic access to the nodule even in the case of portal hypertension, marginal 
neoplastic portal vein thrombosis close to tumor nodule). We considered downward stage 
migration in the case of severe comorbidities, advanced age, strategical localization of the 
nodules. hypovascular pattern hindering chemoembolization, refusal to the proposed 
treatment. 
Retreatment of patients who failed to achieve a complete response was decided by MDT as 
follows: RFTA was repeated once in patients with incomplete tumor necrosis; TACE was 
repeated until complete response or demonstrated progression. Sorafenib dose was 
reduced by 50% in case of grade 2 toxicity whereas it was discontinued whenever tumor 
progressed or grade 3-4 side-effects did not improve following 7 days discontinuation.  
A second-line treatment was proposed by MDT for patients with tumor progression, or unfit 
to further cycles of first-line treatment due to technical constraints, like failure of 
catheterization of the feeding artery, residual tumor not manageable with the first-line 
treatment, or tumor recurrence.  The same policy was adopted for third- and forth line 
treatments. Patients were restaged and BCLC recalculated before each line of treatment.   
Patients were followed until death or last available clinical evaluation, up to January 2014.   
Patients treated out of AASLD guidelines were split between those who underwent 
therapies offered to the next best or to the next worst stage, and the outcome compared to 
that of patients treated according to the standard of care.    
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The study was performed in agreement with the 1975 Declaration of Helsinki and it was 
approved by ethic committee Milano area B. 
 
Statistical analysis 
The baseline characteristics of the patients are expressed as median and range or count and 
proportion. Characteristics of patients treated according to or out of AASLD 
recommendation were compared by chi-square test and Student’s t-test. Estimated survival 
function was calculated by the Kaplan-Meier method and survival curves were compared by 
log-rank test. All information about variables were collected at the time of enrollment. 
Variables considered for univariate analysis were: age, gender, performance status (PS), 
number of HCC nodules, maximum diameter of HCC nodules, portal vein neoplastic 
infiltration, ascites, porto-systemic encephalopathy (PSE), prothrombin time (INR), serum 
AFP, bilirubin, albumin, creatinine, etiology of the underling chronic liver disease, 
concordance to AASLD therapeutic algorithm. The median value of continuous variables 
such as age, albumim creatinine, bilirubin, PT (INR) were the cut-off points used to generate 
two groups of patients. The same criteria were applied for BCLC A, B and C patients. 
Different cut-off points were defined for each BCLC stage. The univariate analysis and the 
Cox proportional hazards regression were used to evaluate overall survival in the whole 
series of patients and repeated for each BCLC stage. Variables with a p-value less than 0.10 
at univariate analysis were introduced in the Cox model. To evaluate the influence on 
survival of the disagreement to AASLD guidelines in the MDT treatment decision, 
characteristics of patients treated according to or out off guidelines were compared and the 
Cox model was repeated adjusting for those variables related to liver function with a p-value 
less than 0.10. To reduce possible colinearities, redundant variables were not introduced in 
the final model of multivariate analysis. A p value <0.05 was considered statistically 
significant. Calculations were done with the Stata 10.0 statistical package (Stata, College 
Station, Texas, USA). 
 
RESULTS 
The study population included 370 patients, 280 (76%) who were identified through the 
hospital program of US surveillance and 90 (24%) who had been referred from other 
hospitals or general practitioners. All patients had cirrhosis and a majority were in early 
stage BCLC A (Table 1). HCC was radiologically diagnosed in 239 (65%) patients and 
histologically in the remaining 131 (35%). Serum AFP level was ≤ 20 ng/mL in 225 (61%) 
whereas it was greater than 200 ng/mL in 54 (15%) patients, only.  
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Treatment algorithm  
The first line therapy was any radical treatment in 234 (63%) patients, TACE in 90 (24%), 
systemic medical treatment in 34 (9%) and BSC in 12 (3%) (Table 2). TACE was a bridge 
therapy in additional 7 (2%) patients listed to LT. Overall, a first line treatment adherent to 
AASLD recommendations was performed in 268 (72%) patients, including 205 (81%) BCLC 0-
A, 36 (54%) BCLC B, and 27 (53%) BCLC C patients. Radical therapies were offered to 22 
(34%) BCLC B and 7 (14%) BCLC C, TACE to 46 (18%) BCLC A patients and 8 (16%) BCLC C, 
sorafenib to 1 (0.5%) BCLC A and 6 (9%) BCLC B, BSC to 1 (0.5%) BCLC A, 2 (3%) BCLC B and 9 
(17%) BCLC C. Discrepant treatments from AASLD recommendations were 48 (19%) in BCLC 
0-A, 30 (45% BCLC B, 24 (47%) BCLC C. Details on applied treatment and reason for 
discrepancies from AASLD recommendations are reported in Table 3.  
One hundred-seventeen (32%) patients with HCC progression received a second-line 
treatment as did patients with a partial response, stable disease or residual tumor who were 
judged by MDT to be no longer fit to first-line therapies. Thirty-nine (11%) and 9 (2%) 
patients were offered a third-line and a fourth-line treatment, respectively (Table 2). 
Restaging for patients proposed for treatment following the first line therapy is showed in 
Figure 1. Overall, a complete response was obtained in 186 (50%) patients, 165 (45%) after a 
first-line treatment, 22/117 (19%) after a second-line treatment, and 9/39 (23%) after a 
third-line treatment. Thirteen patients (3%) achieved a complete response more than one 
time.  Overall, second-third and forth line of treatment achieved a complete response in 
31/370 (8%) patients.  
HCC recurred in 6 (17%) of the 36 transplanted patients: 2 BCLC A4 who received LT as first-
line treatment, 2 BCLC A4 and 2 BCLC B who received LT as rescue therapy after resection. 
 
Survival 
During a median follow-up of 25 months (range 1-149), 105 (28%) patients died, 41 (16%) 
BCLC A, 25 (38%) BCLC B and 39 (74%) BCLC C. Along the same period 5 (1%) patients were 
lost (4 in BCLC A, and 1 in BCLC C).  
The mean yearly mortality rate of the overall cohort was 11.5%, corresponding to a 1, 3, 5 
year overall survival of 92%, 69%, and 58% respectively. The mean mortality rate was 5.9% 
in BCLC A, 16.4% in BCLC B, and 57.0% in BCLC C. The corresponding 1, 3, 5 year survival 
rates were 99%, 84% and 72% in BCLC A, 95%, 55%, 42% in BCLC B and 58%, 13%, 6%, in 
BCLC C, respectively (Figure 2). In BCLC A the mean mortality rate was lower in patients 
treated according to AASLD recommendations than in patients otherwise treated (5.0% vs 
10.4%, respectively, p = 0.004), corresponding to a 1, 3, 5 year survival of 100%, 86%, 77% vs 
93%, 75%, 47% respectively (Figure 3a). The treatment migration to a better stage was 
associated to a lower mortality rate as compared to standard of treatment in BCLC B (8.6% 
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vs 20.7%, p=0.029) corresponding to a  1, 3, 5 year survival of 100%, 74%, 67% vs 100%, 
43%, 23%, respectively (Figure 3b), as well as in BCLC C (42.6% vs 59%, p = 0.04) , 1, 3, 5 yr 
survival 79%, 39%, 0% vs 42%, 1%, 0%, respectively (Figure 3c). On the other hand in BCLC B 
and in BCLC C stage no significant differences were observed between patients treated 
according to recommendation and those treated with a treatment migration to a lower 
stage (mean mortality rate 36.9% in BCLC B and 50.4 % in BCLC C, p = 0.10 and p = 0.5 
respectively).  
Table 4 reports predictors of survival by univariate analysis in the whole series of patients 
and according to BCLC stage. By multivariate analysis, independent predictors of survival 
were performance status (H.R. 4.0 ,95% C.I. 1.8-9.0, p=0.001), number of the nodules (H.R. 
1.1, 95% C.I. 1.0-1.2, p<0.001), maximum diameter of the nodules (H.R. 1.7, 95% C.I. 1.3-2.3, 
p<0.001), neoplastic portal vein thrombosis (H.R 2.6 ,95% C.I. 1.3-4.5, p=0.006), ascites (H.R. 
2.4, 95% C.I. 1.5-3.9, p<0.001), and AFP (H.R. 1.8, 95% C.I. 1.4-2.4, p < 0.001) (Table 5). The 
same table reports results of multivariate analysis performed in each BCLC stage. 
Independent predictors of mortality were maximum diameter of the nodules (H.R. 1.9, 95% 
C.I. 1.2-3.1, p=0.008), presence of ascites (H.R. 2.0, 95% C.I. 1.0-4.1, p=0.05) and 
concordance to AASLD guidelines (H.R. 2.8, 95% C.I. 1.3-5.8, p=0.006) in BCLC A, AFP (HR 
2.7, 95% C.I. 1.6-4.5, p=0.001) and concordance to AASLD guidelines (H.R. 2.9, 1.5-5.5, 
p=0.002) in BCLC B, while no independent predictors were detected in BCLC C. 
 
DISCUSSION 
We aimed to assess to which extent adherence to AASLD recommendations impacts on the 
outcome of treatment of HCC in a cohort of patients mirroring the general population 
attending any referral center for liver disease in Italy.19-21 However, in our study the 
proportion of patients undergoing follow-up and some therapies was higher than in other 
cohorts referred to multicentric studies of the same geographic area 22,23. This could 
represent an indirect evidence of benefits determined by having access to all the 
therapeutic options, including OLT, as a tertially referral centre. Nevertheless, taking the 
AALSD recommendations as our standard of care for HCC, 28% of our patients ultimately 
failed to receive the recommended treatment to the point that even in the best prognostic 
group (BCLC 0-A), 19% of patients missed any radical treatment. This finding suggests that 
despite International Guidelines are accepted and embedded in the clinical practice, 
violations cannot be prevented 24, even in the presence of academic professionals in a 
MDTs.25 Our practice resulted in lower rates of guidelines violations compared to 24% in 
BCLC 0 and 36% in BCLC A reported in an academic Hospital in South Korea14, 46% in BCLC 0-
A patients treated in an academic center15 in Italy, 34% in Spain26 and Egypt16, and to 40% 
rates in BCLC 0-A patients attending primary care hospitals8 in Italy.  
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Not surprisingly, a major reason for a suboptimal adherence to AASLD guidelines was the 
prevalence of severe co-morbidities and strategic tumor localization, two variables of 
prognostic value that in fact are overlooked in the BCLC staging system.  
In our setting, while a radiological complete response was achieved in the 66% of BCLC 0-A 
patients treated according to AASLD recommendations, the success rate was 28% only in 
patients treated out of guidelines, thereby causing more patients to require additional 
treatments. This translated in a significant difference in survival, with 77% of BCLC 0-A 
patients treated according to AASLD guidelines surviving at 5 years compared to 47% of 
patients who received off recommendations treatments. This survival rate was quite similar 
to that reported in literature for patients treated in the same stage, ranging between 40-
70%.6 Enforcing the concept of treatment stage migration, it was no surprise to find that 
BCLC B patients receiving radical therapies had a better outcome compared to patients 
treated with TACE (p = 0.029), which represents the standard of care for this stage. This 
observation does not devalue the evidence-based guideline appropriateness, but highlights 
the added value of MDT which considers variables not included in the BCLC 
recommendations. It is well known that BCLC B stage include a wide clinical heterogeneity27, 
therefore, it can be expected that some intermediate-stage patients may benefit from 
treatments other than TACE, including resection and ablation, as suggested by the Japanese 
society and the National Comprehensive Cancer Network.28,29 On the other hand, the 
outcome of treatment did not worsen when patients were shifted to the SOC treatment 
options for a more advanced stages, probably as a consequence of the low number patients 
included. The evidence that concordance to the guidelines resulted as an independent 
predictor of survival could be a consequence of the heterogeneity in BCLC B stage. Not 
surprisingly, in a such wide motely stage, also AFP, a well-recognized marker of tumor 
dedifferentiation, was an independent predictor of survival, a data which speaks in favor of 
tumor biology as a relevant determinant of prognosis. 
Whereas the multivariate analysis failed to identify any predictors of survival in BCLC C 
patients, we underline that even in this stage some patients can benefit of treatment 
migration to the upper stage. This happened mainly in the case of patients classified in BCLC 
C because of performance status 1 and/or peripheral neoplastic portal vein thrombosis, 
which “per-se” are not an absolute contraindication to TACE, or RFTA. We should not ignore 
that a favorable outcome of other than sorafenib treatments was reported in patients with 
advanced cancer by a retrospective study in France comparing TACE and sorafenib30 and by 
a multinational study with a surprisingly 31% rate of 5-year survival in 169 cirrhotic patients 
with advanced HCC who underwent hepatic resection.31 Our data support these 
observations. In fact, one third of our BCLC C patients underwent treatment migration to 
the next best stage, resulting in 1, 2, 3 year survival of 88%, 44%, and 26% respectively, with 
a median survival of 23 months, significantly better than the 43%, 24%, 6%, median survival 
of 9.5 months, observed in patients treated with sorafenib. For the sake of evidence-based 
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medicine, however, it should be reiterated that both applicability and clinical benefits of 
other than sorafenib treatment modalities in BCLC C patients, need to be validated by a RCT.  
Our study emphasizes the relevance of HCC therapy following to the first-line treatment, 
reporting the rate of complete response to the second-third and fourth lines. Our policy was 
to decide treatment lines after the first option, according to guidelines referred to post-
treatment staging. As it happened for the first line, many therapies were dispensed out of 
guidelines. Whereas this policy is difficult to standardize, we underline the outstanding 
complete response rates reported in the 21% of patients who underwent a second line of 
therapy and in the 15% of those who underwent a third  line, a finding mainly observed in 
BCLC A patients and even in 9% of BCLC B patients.   
Whereas this study was not designed to provide an algorithm for the multimodality 
treatment of HCC, it clearly suggests the relevance of the multimodality approach, largely 
applied worldwide in the clinical practice. 
In conclusion, we confirm discrepancies between field practice and therapeutic algorithms 
recommended by AASLD. HCC multimodality treatment including other than first line 
therapy is common in clinical practice and it impacts on the achievement of complete 
response. The same wide clinical heterogeneity of HCC patients may also impact on field 
practice as it may favor discrepancies with the treatment decision making process 
recommended by the guidelines released by International Societies. We highlighted 
criticisms in the recommendations for the treatment of patients in BCLC B and C classes, 
which need to be amended in prospective trials, to refine personalized treatment 
algorithms for HCC patients, whose clinical profile is not accounted for by International 
guidelines.  
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Table 1: Baseline characteristics of patients  
                             Total BCLC 0-A BCLC B BCLC C 
No. of patients 370 253 66 51 
Age, yr median (range) 
     30-39 
     40-49 
     50-59 
     60-69 
     70-79 
     80-89 
68 (33-86) 
3 (1%) 
21 (6%) 
61 (16%) 
123 (33%) 
141 (38%) 
21 (6%) 
68 (33-86) 
1 (1%) 
18 (7%) 
44 (17%) 
83 (33%) 
98 (39%) 
9 (3%) 
68 (46-85) 
- 
3 (5%) 
8 (12%) 
25 (38%) 
22 (33%) 
8 (12%) 
68 (35-84) 
2 (4%) 
- 
9 (18%) 
15 (29%) 
21 (41%) 
4 (8%) 
Male gender, No.  272 (73%) 182 (72%) 45 (68%) 45 (85%) 
Etiology, No.      
HBV only 33 (9%) 20 (8%) 9 (14%) 4 (8%) 
HCV only 217 (59%) 160 (63%) 30 (45%) 27 (53%) 
Alcohol only 41 (11%) 23 (9%) 10 (15%) 8 (15%) 
Mixed * 55 (15%) 34 (14%) 15 (23%) 6 (11%) 
Others ** 24 (6%) 16 (6%) 2 (3%) 6 (11%) 
Albumin, mg/dL, median (range) 3.9 (2.2-5.1) 4.0 (2.5-5.0) 3.8 (2.2-5.1) 3.9 (2.9-5.0) 
Bilirubin, mg/dL, median (range) 1.1 (0.1-8.2) 1.0 (0.2-4.1) 1.2 (0.1-3.1) 1.3 (0.1-8.2) 
INR, median (range) 1.1 (0.6-3.1) 1.1 (0.6-2.2) 1.2 (0.9-1.4) 1.2 (0.9-3.1) 
Creatinine, mg/dL, median (range) 0.9 (0.4-3.5) 0.9 (0.4-2.1) 0.9 (0.5-3.5) 1.0 (0.5-1.8) 
AFP, ng/mL, No.     
<20 225 (61%) 177 (70%) 33 (50%) 15 (28%) 
20-200 91 (24%) 57 (23%) 18 (27%) 16 (30%) 
>200 54 (15%) 17 (7%) 15 (23%) 22 (42%) 
Ascites, No. 80 (22%) 39 (16%) 19 (29%) 22 (42%) 
PSE, No. 19 (5%) 8 (3%) 3 (5%) 8 (15%) 
ECOG PS = 0, No.  360 (97%) 253 (100%) 66 (100%) 43 (81%) 
Child-Pugh score, No.      
A 285 (77%)  203 (81%) 45 (68%) 37 (70%) 
B 85 (23%) 48 (19%) 21 (32%) 16 (30%) 
MELD score,  (range) 9.0 (6-21) 8.8 (6-18) 9.4 (6-21) 9.4 (6-17) 
No. of nodules,  No.     
1 205 (55%) 184 (73%) 0 21 (40%) 
2-3 110 (30%) 67 (27%) 33 (50%) 10 (19%) 
>3 55 (15%) 0 33 (50%) 22 (41%) 
Diameter of nodules, cm, No.      
< 3  244 (66%) 198 (79%) 26 (39%) 20 (38%) 
3-5 81 (22%) 42 (17%) 25 (38%) 14 (24%) 
> 5 45 (12%) 11 (4%) 15 (23%) 19 (36%) 
Neoplastic portal thrombosis, No.  24 (6%) 0 0 24 (45%) 
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* Mixed: HBV+HCV = 9, HBV+HDV = 6, HBV+Alcohol = 7, HCV+Alcohol = 25, HBV+HDV+Alcohol = 2, 
HCV+NASH = 1,  
   HCV+Genetic Hemochromatosis = 1, NASH+Alcohol = 3, NASH+HCV =1, Alcohol+Genetic Hemochromatosis = 1 
** Others: NASH = 12, Cryptogenetic = 9, Primary Biliary Cholangitis = 2, Autoimmune = 1   
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Table 2: Radiological complete response (CR) rates to treatments applied according to BCLC classification   
 
                                  
Treatment 
                                 First line                           Second line                         Third line  Fourth line 
 BCLC (CR/Total) BCLC (CR/Total) BCLC (CR/Total) BCLC (CR/Total) 
 Total A B C Total A B C Total A B C Total A B C 
OLT 27/29 
(93%) 
24/26 
(92%) 
3/3  
(100%) 
0/0 0/1 
(0%) 
0/0 0/1 
(0%) 
0/0 4/5 
(80%) 
4/4 
(100%) 
0/1 
(0%) 
0/0 0/2 
(0%) 
0/2 
(0%) 
0/0 0/0 
Resection 39/59 
(66%) 
36/52 
(69%) 
3/6  
(50%) 
0/1 
(0%) 
4/7 
(57%) 
4/6 
(67%) 
0/1 
(0%) 
0/0 1/1 
(100%) 
1/1 
(100%) 
0/0 0/0 0/0 0/0 0/0 0/0 
Local ablation 80/146 
(55%) 
76/127 
(60%) 
4/13  
(31%) 
0/6 
(0%) 
8/33 
(24%) 
4/22 
(18%) 
4/11  
(36%) 
0/0  0/3  
(0%) 
0/0 0/3  
(0%) 
0/0 0/0 0/0 0/0 0/0 
TACE 19/90 
(21%) 
13/46 
(28%) 
5/36  
(14%) 
1/8 
(12%) 
10/53 
(19%) 
9/25 
(36%) 
1/23  
(4%) 
0/5 
(0%) 
4/14 
(28%) 
4/8 
(50%) 
0/4 
(0%) 
0/2 
(0%) 
0/2 
(0%) 
0/0 0/2 
(0%) 
0/0 
Sorafenib 0/34  
(0%) 
0/1  
(0%) 
0/6  
(0%) 
0/27 
(0%) 
0/23 
(0%) 
0/2 
(0%) 
0/3  
(0%) 
0/18 
(0%) 
0/16 
(0%) 
0/0 0/9 
(0%) 
0/7 
(0%) 
0/5 
(0%) 
0/2 
(0%) 
0/2 
(0%) 
0/0 
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BSC 0/12 
(0%) 
0/1 
(0%) 
0/2 
(0%) 
0/9 
(0%) 
            
Total 165/370 
(45%) 
148/253 
(58%) 
15/66 
(23%) 
2/51 
(4%) 
22/117 
(19%) 
17/55 
(31%) 
5/39 
 (13%) 
0/23 
(0%) 
9/39 
(23%) 
9/13 
(69%) 
0/17 
(0%) 
0/9 
(0%) 
0/9 
(0%) 
0/7 
(0%) 
0/4 
(0%) 
0/3 
(0%) 
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Table 3: Reasons for discrepancies with AASLD recommendations 
 
 First line treatment proposed, No (%) 
 
Therapy for the next 
best stage 
Standard of care 
Therapy for the next 
worst stage 
BCLC 0-A (No. 253) 0 205 (81%) 48 (19%)* 
BCLC B (No. 66) 22 (34%)** 36 (54%) 8 (12%)*** 
BCLC C (No. 51) 15 (29%)§ 27 (53%) 9 (18%)ˤ 
 
* 15  TACE for Child-Pugh 7-9, 2 for age > 80 years, 3 for comorbidities (1 previous stroke, 2 previous ischemic heart disease, which 
intrese anesthesiological risk),  26 for strategical localization, 1 sorafenib for strategical localization and hypovascular pattern, 1 BSC 
for refusal of any therapy. 
**3 OLT after downstaging, 4 resection of nodules > 3cm with satellites and 2 for multinodular left lobe localization only, 13 RFTA in 
nodules >3cm with satellites 
***6 sorafenib for hypovascular pattern, 2 BSC for refusal of any therapy 
§ 1 resection of peripheral nodules with marginal neoplastic portal vein infiltration, 2 RFTA of nodule with peripheral portal vein 
thrombosis, 3 RFTA in patients with performance status 1, 1 RFTA for localized seeding surgically removed, 4 TACE in nodules with 
marginal neoplastic portal vein infiltration and 4 TACE for performance status 1  
ˤ 4 BSC for refusal of any therapy, 5 BSC for Child-Pugh B7-9 
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Table 4: Predictors of survival by univariate analysis  
 
                                                              p value (*) 
Predictors of survival 
Total 
(No. 370) 
BCLC 0-A 
(No. 253) 
BCLC B 
(No. 66) 
BCLC C 
(No. 51) 
Age 
(< vs ≥  median value) ** 
0.94 0.90 0.80 0.66 
Gender  
(Male, Female) 
0.67 0.94 0.30 0.76 
Etiology  
(HBV, HCV, ETOH, Mixed, Others) 
0.08 0.22 0.74 0.018 
Albumin  
(< vs ≥  median value) ** 
0.086 0.09 0.98 0.71 
Bilirubin 
(< vs ≥  median value) ** 
0.025 0.83 0.33 0.11 
INR 
(< vs ≥  median value) ** 
0.39 0.19 0.78 0.28 
Creatinine 
(< vs ≥  median value) ** 
0.34 0.46 0.96 0.28 
AFP  
(0, 20-200, >200 ng/mL)  
0.0000 0.30 0.0006 0.22 
Ascites 
(no vs yes) 
0.0004 0.004 0.18 0.77 
PSE  0.0016 0.009 0.50 0.50 
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(no vs yes) 
ECOG PS 
(0, > 0) 
0.016 - - 0.21 
No. of nodules   
(1, 2-3, >3) 
0.0000 0.16 0.93 0.09 
Diameter of nodules 
(< vs ≥  median value)  ** 
0.0000 0.04 0.63 0.20 
Neoplastic portal vein thrombosis 
(no vs yes) 
0.0000 - - 0.63 
Concordance to AASLD algorithm 
(upward, recommended, downward)  
0.011 0.004 0.0064 0.1384 
 
* = Log-rank test  
** =  Median reported in table 1 
n.a. = not applicable 
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Table 5: Independent predictors of survival by multivariate analysis according to Cox Model 
 
HR (95% C.I), p value 
Predictors of survival 
Total 
(No. 370) 
BCLC A 
(No. 253) 
BCLC B 
(No. 66) 
BCLC C 
(No. 51) 
Age 
(< vs ≥  median value) ** 
- - - - 
Gender  
(Male, Female) 
- - - - 
Etiology  
(HBV, HCV, ETOH, Mixed, Others) 
1.1 (0.9-1.3), 0.51 - - 1.0 (0.8-1.4), 0.73 
Albumin  
(< vs ≥  median value) ** 
0.9 (0.6-1.5), 0.83 1.3 (0.7-2.6), 0.42 - - 
Bilirubin 
(< vs ≥  median value) ** 
1.2 (0.8-1.9), 0.29 - - - 
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INR 
(< vs ≥  median value) ** 
- - - - 
Creatinine 
(< vs ≥  median value) ** 
- - - - 
AFP  
(0, 20-200, >200 ng/mL)  
1.8 (1.4-2.4), <0.001 - 2.7 (1.6-4.5), 0.001 - 
Ascites 
(no vs yes) 
2.4 (1.5-3.9), <0.001 2.0 (1.0-4.1), 0.05 - - 
PSE  
(no vs yes) 
1.4 (0.8-2.5), 0.28 2.2 (0.9-5.8), 0.10 - - 
ECOG PS 
(0, > 0) 
4.0 (1.8-9.0), 0.001 - - - 
No. of nodules   
(1, 2-3, >3) 
1.1 (1.0-1.2) <0.001 - - 1.4 (0.9-2.0), 0.10 
Diameter of nodules 1.7 (1.3-2.3), <0.001 1.9 (1.2-3.1), 0.008 - - 
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(< vs ≥  median value)  ** 
Neoplastic portal vein thrombosis 
(no vs yes) 
2.6 (1.3-4.5), 0.006 - - - 
Conco dance to AASLD algorithm 
(upward, recommended, downward)  
1.2(0.8-1.6), 0.38 2.8 (1.3-5.8), 0.006 2.9 (1.5-5.5) 0.002 - 
 
* = Log-rank test  
** =  Median reported in table 1 
n.a. = not applicable 
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LEGEND TO FIGURES 
Figure 1: Restaging of HCC according to BCLC classification and treatment-lines 
 
Figure 2: Overall survival curves according to BCLC: 
Solid line = BCLC A, median survival 29 months (95% C.I. 26.0-33.0) 
Dotted line = BCLC B, median survival 23.5 months (95% C.I. 20.1-30.5) 
Dashed line = BCLC C. median survival 12 months (95% C.I. 8.0-18.0). 
BCLC A vs B, p < 0.0001; BCLC A vs C, p < 0.0001; BCLC B vs C, p < 0.0001. 
 
Figure 3a: Overall survival curves in BCLC A patients, according to received treatment:  
Solid line = Treatment according to AASLD recommendation, median survival 31 months 
(95%-C.I. 27.6-35.0) 
Dotted line = Downward treatment stage migration. Median survival 21 months (95% C.I. 
17.8-31.1). 
Recommended vs Downward treatment, p = 0.004. 
 
Figure 3b: Overall survival curves in BCLC B patients, according to received treatment:  
Dashed line = upward treatment stage migration, median survival 33.5 months (95% C.I. 
25.8-48.1) 
Solid line = Treatment according to AASLD recommendation, median survival 21 months 
(95% C.I. 17.0-25.0) 
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Dotted line = downward treatment stage migration, median survival 16 months (95% C.I. 
2.1-30.0) 
Upward treatment vs Recommended, p = 0.029; Recommended treatment vs Downward, p = 
0.099. 
 
Figure 3c: Overall survival curves in BCLC C patients, according to received treatment:  
Dashed line = Upward treatment stage migration, median survival 21 months (95% C.I. 11.5-
26.8) 
Solid line = treatment according to AASLD recommendation, median survival 9 months 
(95% C.I. 4.8-16.0) 
Dotted line = downward treatment stage migration, median survival 14 months (95% C.I. 
3.0-21.8) 
Upward treatment vs Recommended, p = 0.04; Recommended treatment vs Downward, p = 
0.43.  
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